Amgen price target raised to $328 from $322 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $328 from $322 and keeps an Equal Weight rating on the shares. Amgen posted a Q4 beat and gave 2025 revenue and EPS guidance that bracketed consensus, which the firm views as a positive given questions ahead of the quarter, the analyst tells investors.